Evolocumab had no effect in young women with familial hypercholesterolemia

Authors

  • K. S. Benimetskaya Research Institute of Internal and Preventive Medicine - Branch of Federal State Budget Scientific Institution The Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Science, Novosibirsk National Research State University
  • K. V. Makarenkova Research Institute of Internal and Preventive Medicine - Branch of Federal State Budget Scientific Institution The Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Science
  • L. D. Latyntseva Research Institute of Internal and Preventive Medicine - Branch of Federal State Budget Scientific Institution The Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Science
  • O. V. Tsygankova Research Institute of Internal and Preventive Medicine - Branch of Federal State Budget Scientific Institution The Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Science, Novosibirsk State Medical University
  • S. V. Astrakov Novosibirsk National Research State University
  • E. V. Shachtschneider Research Institute of Internal and Preventive Medicine - Branch of Federal State Budget Scientific Institution The Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Science
  • Yu. I. Ragino Research Institute of Internal and Preventive Medicine - Branch of Federal State Budget Scientific Institution The Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Science
  • M. I. Voivode Research Institute of Internal and Preventive Medicine - Branch of Federal State Budget Scientific Institution The Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Science

Keywords:

familial hypercholesterolemia, Compound heterozygous, low density lipoprotein cholesterol, atherosclerosis, Xanthomatosis, PCSK9 inhibitors, evolocumab

Abstract

Familial hypercholesterolemia is an autosomal dominant genetic disorder characterised by a significant increase of blood cholesterol level, premature development andprogression of atherosclerosis. In case of homozygous form total cholesterol, level exceeds 14 mmol/l. The article presents the case of absence of PCSK9 inhibitor effect in a young woman with familial hypercholesterolemia, compound heterozygous for the low density lipoprotein receptor gene, who needs therapy with PCSK9 inhibitors, according to the Russian guidelines on the diagnosis and treatment of familial hypercholesterolemia.

Downloads

Download data is not yet available.

Downloads

Published

2018-03-26

How to Cite

Benimetskaya K. S., Makarenkova K. V., Latyntseva L. D., Tsygankova O. V., Astrakov S. V., Shachtschneider E. V., Ragino Y. I., Voivode M. I. Evolocumab had no effect in young women with familial hypercholesterolemia // The Journal of Atherosclerosis and Dyslipidemias. 2018. VOL. № 1 (30). PP. 67–71.

Issue

No. 1 (30) (2018)

Section

Clinical Case

Most read articles by the same author(s)

1 2 > >>